Skip to main content
    H

    Halozyme Therapeutics Inc (HALO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $96.50
    -3.77 (-3.76%)

    Market Cap: $11.43B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Halozyme Therapeutics Inc (HALO) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Halozyme Therapeutics (HALO) to earn $8.89 per share in the fiscal year ending Dec 31, 2026, on revenue of $1.90B. Of 9 analysts, 7 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 3 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 9 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 78% of the ratings.

    RatingAnalystsShare
    Strong Buy222.2%
    Buy555.6%
    Hold222.2%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    9

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus rises 19.1% and revenue estimates rise 14.7%.

    Fiscal year ending Dec 31, 2026
    $8.89
    EPS consensus, revenue $1.90B
    Fiscal year ending Dec 31, 2027
    $10.59
    EPS consensus, revenue $2.18B
    Next report
    Jan 26, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$8.89$8.73 to $9.046$1.90B$1.88B to $1.93B9
    Dec 31, 2027$10.59$9.60 to $11.485$2.18B$2.09B to $2.35B8

    Quarterly Estimates

    The EPS consensus falls from $2.70 for the quarter ending Dec 31, 2026 to $2.33 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$2.70$2.53 to $2.9211$560.07M$529.20M to $603.03M9
    Mar 31, 2027$2.33$2.32 to $2.343$488.72M$478.00M to $499.43M2

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 7 upward and 1 downward EPS revisions. Raises outnumber cuts in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202631
    Fiscal year ending Dec 31, 202720
    Quarter ending Mar 31, 202720

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 3.6% from $8.58.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$8.89$8.84$8.58$8.58$8.58+3.6%
    Fiscal year ending Dec 31, 2027$10.59$10.68$10.39$10.39$10.39+1.9%
    Quarter ending Mar 31, 2027$2.33$2.33$2.34$2.34$2.34-0.4%

    Frequently Asked Questions About HALO

    What is the HALO stock forecast?

    Consensus analyst estimates put Halozyme Therapeutics's EPS at $8.89 for the fiscal year ending Dec 31, 2026, on revenue of $1.90B. The consensus rating from 9 analysts is Buy.

    How do analysts rate HALO stock?

    Of 9 analysts covering Halozyme Therapeutics, 2 rate it Strong Buy, 5 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from HALO next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $8.89, with estimates from $8.73 to $9.04 from 6 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $10.59, with estimates from $9.60 to $11.48 from 5 analysts.

    What revenue do analysts expect from Halozyme Therapeutics next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $1.90B, with estimates from $1.88B to $1.93B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $2.18B, with estimates from $2.09B to $2.35B.

    How many analysts cover HALO?

    9 analysts rate Halozyme Therapeutics stock, and 6 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.